One vision. One ambitious goal.
We believe collaboration breeds innovation. FerGene is committed to working with partners that share our vision to revolutionize the treatment of bladder cancer and advance the field of uro-oncology.
Bacillus Calmette-Guérin (BCG) remains the first-line standard of care for people living with high-grade NMIBC, but more than 40% of patients will experience recurrence after BCG treatment, leaving them with few effective alternatives to life-altering radical cystectomy (bladder removal).5-8
People living with BCG-unresponsive high-grade NMIBC need alternative treatment options.
References: 1. SEER cancer stat facts: bladder cancer. National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed March 26, 2020. 2. Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. American Urological Association Education and Research, Inc. 2016. 3. US Food and Drug Administration. Drug approval package. Valstar (valrubicin) sterile solution. September 25, 1998. Accessed March 26, 2020. 4. Valstar (valrubicin) Prescribing Information. Endo Pharmaceuticals Solutions, Inc. 2017. 5. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol. 2000;163(4):1124-1129. 6. Hussain MH, Wood DP, Bajorin DF, et al. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol. 2009;27(34): 5680-5684. 7. Siddiqui MR, Grant C, Sanford T, Agarwal PK. Current clinical trials in non-muscle invasive bladder cancer (NMIBC). Urol Oncol. 2017;35(8):516-527. 8. Packiam VT, Johnson SC, Steinberg GD. Non-muscle-invasive bladder cancer: intravesical treatments beyond bacille Calmette-Guérin. Cancer. 2017;123(3):390-400.